Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on November 20, 2023, the compensation committee of the company's board of directors granted fourteen new non-executive employees options to purchase an aggregate of 221,805 shares of the company's common stock, and granted sixteen new non-executive employees an aggregate of 182,068 Restricted Stock Units (RSUs). Each stock option has an exercise price per share equal to $4.38 per share, which was the closing trading price of the company's common stock on the date of grant. The stock options and RSUs were granted as inducements material to each employee's decision to enter into employment with Ardelyx, in accordance with Nasdaq Listing Rule 5635(c)(4).
馬薩諸塞州沃爾瑟姆，2023 年 11 月 21 日（GLOBE NEWSWIRE）——一家生物製藥公司 Ardelyx, Inc.（納斯達克股票代碼：ARDX）今天宣佈，2023 年 11 月 20 日，公司董事會薪酬委員會向十四名新的非執行員工授予購買該藥物的選擇權共計221,805股公司普通股，並向16名新的非執行員工授予合計182,068股限制性股票庫存單位 (RSU)。每種股票期權的每股行使價等於每股4.38美元，這是授予當日公司普通股的收盤交易價格。根據納斯達克上市規則第5635 (c) (4) 條，股票期權和限制性股票單位是激勵每位員工決定在Ardelyx就業的手段。
Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the employee's first date of employment, and the remaining 75% of shares vesting monthly thereafter. Each RSU vests over four years, with 25% vesting on the first company designated quarterly RSU vest date following the first anniversary of the employee's first day of employment and the remaining 75% of shares vesting quarterly thereafter. Each stock option has a 10-year term and each option and RSU is subject to the terms and conditions of the company's 2016 Employment Commencement Incentive Plan and the award agreement covering the grant.
每種股票期權在四年內歸屬，其中25％的股票在員工首次就業一週年之際歸屬，其餘75％的股票在此後每月歸屬。每個 RSU 的歸屬期爲四年，其中 25% 的歸屬期限爲員工入職第一天一週年之後的第一家公司指定的季度RSU歸屬日期，其餘75％的股份在此後每季度歸屬。每個股票期權的期限爲10年，每個期權和RSU都受公司2016年就業啓動激勵計劃的條款和條件以及涵蓋補助金的獎勵協議的約束。
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA (tenapanor) and XPHOZAH (tenapanor), as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin has received approval for PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
關於 Ardelyx, Inc.
Ardelyx成立的使命是發現、開發和商業化一流的創新藥物，以滿足尚未滿足的重大醫療需求。Ardelyx 有兩款商用產品在美國獲得批准，即 IBSRELA （tenapanor）和 XPHOZAH （tenapanor），以及早期的管道候選人。Ardelyx 已達成在美國境外開發 tenapanor 並將其商業化的協議。協和麒麟已獲得 PHOZEVEL 的批准 （tenapanor）用於治療日本的高磷血癥。復星醫藥已在中國提交了用於治療高磷血癥的替那帕諾的新藥申請。Knight Therapeutics 在加拿大將 IBSRELA 商業化。欲了解更多信息，請通過 X（前身爲 Twitter）、LinkedIn 和 Facebook 訪問並聯系我們。
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
投資者和媒體聯繫人：
凱特琳·洛伊
clowie@ardelyx.com
譯文內容由第三人軟體翻譯。